Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Diamond study-8: Canagliflozin effects on renal oxygenation by BOLD MRI in type 2 diabetes
jRCTs051200047Completed
- Sponsor
- Mitsubishi Tanabe Pharma Corporation
- Start
- Sep 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of canagliflozin in type 2 diabetes mellitus (T2DM), sponsored by Mitsubishi Tanabe Pharma Corporation. Primary endpoint: Change in renal T2* value by BOLD MRI. Started Sep 2020; status: completed.
02
Drugs
canagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on jRCTs051200047.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs051200047.